查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1541790

2024-2032 年按治疗类型（药物类别、微创手术、雷射治疗等）和地区分類的良性前列腺增生治疗市场报告

Benign Prostatic Hyperplasia Treatment Market Report by Treatment Type (Drug Class, Minimally Invasive Surgeries, Laser Therapy, and Others), and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 148 Pages | 商品交期: 2-3个工作天内

价格

IMARC Group年，全球良性前列腺增生治疗市场规模达119亿美元。

良性摄护腺增生（BPH）或良性摄护腺肥大是指导致尿道阻塞的摄护腺非癌性增大。这种情况会导致尿滞留困难、膀胱结石、因过度充盈而导致的尿失禁、膀胱敏感性增加以及尿路感染。 BPH 的一些常用治疗替代方案包括处方药、主动观察或监测、单一药物和联合疗法、植物疗法以及微创 (MI) 和侵入性手术。这些手术通常透过电切镜、射频消融装置、泌尿外科雷射、前列腺支架和植入物等设备进行。

全球泌尿系统疾病的盛行率不断上升，是创造积极市场前景的关键因素之一。此外，老年人口的增加更容易患此类严重疾病，这也推动了市场的成长。医疗保健提供者使用 α 受体阻断剂透过放鬆前列腺肌肉和控制患者血压来控制 BPH。与此一致的是，大众的健康意识和对可用治疗替代方案的认识不断提高也促进了市场的成长。此外，各种进步，例如作为一种有效治疗方法的经尿道前列腺电切（TURP）的发展，也起到了其他生长诱导因素的作用。 TURP 是一种内视镜电外科手术，涉及切除前列腺的一部分以减少异常生长引起的阻塞。其他因素，包括个人医疗保健支出能力的提高，以及医疗保健基础设施的显着改善，特别是在发展中国家，预计将进一步推动市场。

本报告回答的关键问题：

  • 迄今为止，全球良性前列腺增生治疗市场表现如何，未来几年将如何表现？
  • COVID-19对全球良性摄护腺增生治疗市场有何影响？
  • 主要区域市场有哪些？
  • 根据治疗类型的市场划分是怎样的？
  • 产业价值链的各个阶段是什么？
  • 该行业的关键驱动因素和挑战是什么？
  • 全球良性摄护腺增生治疗市场的结构如何？
  • 产业竞争程度如何？

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 数据来源
    • 主要来源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球良性摄护腺增生治疗市场

  • 市场概况
  • 市场表现
  • COVID-19 的影响
  • 市场预测

第 6 章：市场区隔：依治疗类型

  • 药品类别
    • 市场趋势
    • 主要类型
      • α-阻断剂
      • 5-α-还原酶抑制剂 (5-ARIs)
      • 磷酸二酯酶 5 酶抑制剂
      • 其他的
    • 市场预测
  • 微创手术
    • 市场趋势
    • 主要类型
      • 经尿道摄护腺电切术 (TURP)
      • 经尿道摄护腺切开术 (TUIP)
      • 经尿道微波热疗 (TUMT)
      • 机器人手术
      • 前列腺尿道提升术
      • 其他的
    • 市场预测
  • 雷射治疗
    • 市场趋势
    • 市场预测
  • 其他的
    • 市场趋势
    • 市场预测

第 7 章：市场区隔：按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲
    • 市场趋势
    • 市场细分：按国家/地区
    • 市场预测

第 8 章：SWOT 分析

  • 概述
  • 优势
  • 弱点
  • 机会
  • 威胁

第 9 章：价值链分析

第 10 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 11 章：价格分析

第 12 章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Abbott Laboratories
    • Allergan plc (AbbVie Inc.)
    • Asahi Kasei Corporation
    • Astellas Pharma Inc.
    • Boehringer Ingelheim GmbH (CH Boehringer Sohn AG & Ko. KG)
    • Boston Scientific Corporation
    • GlaxoSmithKline Plc
    • Pfizer Inc.
    • Sanofi SA
    • Teva Pharmaceutical Industries Ltd.
Product Code: SR112024A2898

The global benign prostatic hyperplasia treatment market size reached US$ 11.9 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 18.1 Billion by 2032, exhibiting a growth rate (CAGR) of 4.6% during 2024-2032.

Benign prostatic hyperplasia (BPH) or benign prostatic hypertrophy refers to the non-cancerous enlargement of the prostate gland that causes blockage in the urethra. This condition causes difficulties in urine retention, bladder stones, incontinence due to overfilling, increased sensitivity of the bladder and infections in the urinary tract. Some of the commonly used treatment alternatives for BPH include prescription drugs, active observation or surveillance, mono drug and combined therapies, phytotherapies and minimally invasive (MI) and invasive surgeries. These surgeries are usually conducted through devices, such as resectoscopes, radiofrequency ablation devices, urology lasers, prostatic stents and implants.

The increasing prevalence of urological disorders across the globe represents one of the key factors creating a positive outlook for the market. Furthermore, the rising geriatric population, which is more susceptible to such critical ailments, is providing a boost to the market growth. Healthcare providers use alpha-blockers to manage BPH by relaxing the prostate muscles and controlling the blood pressure of the patient. In line with this, rising health consciousness and awareness among the masses regarding the available treatment alternatives are also contributing to the market growth. Additionally, various advancements, such as the development of transurethral resection of the prostate (TURP) as an effective treatment procedure, are acting as other growth-inducing factors. TURP is an endoscopic electrosurgical procedure that involves removing a portion of the prostate gland to reduce obstruction caused by the abnormal growth. Other factors, including rising healthcare expenditure capacities of individuals, along with significant improvements in the healthcare infrastructure, especially in the developing countries, are anticipated to drive the market further.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global benign prostatic hyperplasia treatment market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on treatment type.

Breakup by Treatment Type:

Drug Class

Alpha-Blockers

5-Alpha-reductase Inhibitors (5-ARIs)

Phosphodiesterase-5 Enzyme Inhibitors

Others

Minimally Invasive Surgeries

Transurethral Resection of the Prostate (TURP)

Transurethral Incision of the Prostate (TUIP)

Transurethral Microwave Thermotherapy (TUMT)

Robotic Surgeries

Prostatic Urethral Lifts

Others

Laser Therapy

Others

Breakup by Region:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being Abbott Laboratories, Allergan Plc (AbbVie Inc.), Asahi Kasei Corporation, Astellas Pharma Inc., Boehringer Ingelheim GmbH (C.H. Boehringer Sohn AG & Ko. KG), Boston Scientific Corporation, GlaxoSmithKline Plc, Pfizer Inc., Sanofi S.A. and Teva Pharmaceutical Industries Ltd.

Key Questions Answered in This Report:

  • How has the global benign prostatic hyperplasia treatment market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global benign prostatic hyperplasia treatment market?
  • What are the key regional markets?
  • What is the breakup of the market based on the treatment type?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global benign prostatic hyperplasia treatment market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Benign Prostatic Hyperplasia Treatment Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Treatment Type

  • 6.1 Drug Class
    • 6.1.1 Market Trends
    • 6.1.2 Major Types
      • 6.1.2.1 Alpha-Blockers
      • 6.1.2.2 5-Alpha-reductase Inhibitors (5-ARIs)
      • 6.1.2.3 Phosphodiesterase-5 Enzyme Inhibitors
      • 6.1.2.4 Others
    • 6.1.3 Market Forecast
  • 6.2 Minimally Invasive Surgeries
    • 6.2.1 Market Trends
    • 6.2.2 Major Types
      • 6.2.2.1 Transurethral Resection of the Prostate (TURP)
      • 6.2.2.2 Transurethral Incision of the Prostate (TUIP)
      • 6.2.2.3 Transurethral Microwave Thermotherapy (TUMT)
      • 6.2.2.4 Robotic Surgeries
      • 6.2.2.5 Prostatic Urethral Lifts
      • 6.2.2.6 Others
    • 6.2.3 Market Forecast
  • 6.3 Laser Therapy
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Others
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Region

  • 7.1 North America
    • 7.1.1 United States
      • 7.1.1.1 Market Trends
      • 7.1.1.2 Market Forecast
    • 7.1.2 Canada
      • 7.1.2.1 Market Trends
      • 7.1.2.2 Market Forecast
  • 7.2 Asia Pacific
    • 7.2.1 China
      • 7.2.1.1 Market Trends
      • 7.2.1.2 Market Forecast
    • 7.2.2 Japan
      • 7.2.2.1 Market Trends
      • 7.2.2.2 Market Forecast
    • 7.2.3 India
      • 7.2.3.1 Market Trends
      • 7.2.3.2 Market Forecast
    • 7.2.4 South Korea
      • 7.2.4.1 Market Trends
      • 7.2.4.2 Market Forecast
    • 7.2.5 Australia
      • 7.2.5.1 Market Trends
      • 7.2.5.2 Market Forecast
    • 7.2.6 Indonesia
      • 7.2.6.1 Market Trends
      • 7.2.6.2 Market Forecast
    • 7.2.7 Others
      • 7.2.7.1 Market Trends
      • 7.2.7.2 Market Forecast
  • 7.3 Europe
    • 7.3.1 Germany
      • 7.3.1.1 Market Trends
      • 7.3.1.2 Market Forecast
    • 7.3.2 France
      • 7.3.2.1 Market Trends
      • 7.3.2.2 Market Forecast
    • 7.3.3 United Kingdom
      • 7.3.3.1 Market Trends
      • 7.3.3.2 Market Forecast
    • 7.3.4 Italy
      • 7.3.4.1 Market Trends
      • 7.3.4.2 Market Forecast
    • 7.3.5 Spain
      • 7.3.5.1 Market Trends
      • 7.3.5.2 Market Forecast
    • 7.3.6 Russia
      • 7.3.6.1 Market Trends
      • 7.3.6.2 Market Forecast
    • 7.3.7 Others
      • 7.3.7.1 Market Trends
      • 7.3.7.2 Market Forecast
  • 7.4 Latin America
    • 7.4.1 Brazil
      • 7.4.1.1 Market Trends
      • 7.4.1.2 Market Forecast
    • 7.4.2 Mexico
      • 7.4.2.1 Market Trends
      • 7.4.2.2 Market Forecast
    • 7.4.3 Others
      • 7.4.3.1 Market Trends
      • 7.4.3.2 Market Forecast
  • 7.5 Middle East and Africa
    • 7.5.1 Market Trends
    • 7.5.2 Market Breakup by Country
    • 7.5.3 Market Forecast

8 SWOT Analysis

  • 8.1 Overview
  • 8.2 Strengths
  • 8.3 Weaknesses
  • 8.4 Opportunities
  • 8.5 Threats

9 Value Chain Analysis

10 Porters Five Forces Analysis

  • 10.1 Overview
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Degree of Competition
  • 10.5 Threat of New Entrants
  • 10.6 Threat of Substitutes

11 Price Analysis

12 Competitive Landscape

  • 12.1 Market Structure
  • 12.2 Key Players
  • 12.3 Profiles of Key Players
    • 12.3.1 Abbott Laboratories
      • 12.3.1.1 Company Overview
      • 12.3.1.2 Product Portfolio
      • 12.3.1.3 Financials
      • 12.3.1.4 SWOT Analysis
    • 12.3.2 Allergan plc (AbbVie Inc.)
      • 12.3.2.1 Company Overview
      • 12.3.2.2 Product Portfolio
      • 12.3.2.3 Financials
      • 12.3.2.4 SWOT Analysis
    • 12.3.3 Asahi Kasei Corporation
      • 12.3.3.1 Company Overview
      • 12.3.3.2 Product Portfolio
      • 12.3.3.3 Financials
      • 12.3.3.4 SWOT Analysis
    • 12.3.4 Astellas Pharma Inc.
      • 12.3.4.1 Company Overview
      • 12.3.4.2 Product Portfolio
      • 12.3.4.3 Financials
      • 12.3.4.4 SWOT Analysis
    • 12.3.5 Boehringer Ingelheim GmbH (C.H. Boehringer Sohn AG & Ko. KG)
      • 12.3.5.1 Company Overview
      • 12.3.5.2 Product Portfolio
      • 12.3.5.3 SWOT Analysis
    • 12.3.6 Boston Scientific Corporation
      • 12.3.6.1 Company Overview
      • 12.3.6.2 Product Portfolio
      • 12.3.6.3 Financials
      • 12.3.6.4 SWOT Analysis
    • 12.3.7 GlaxoSmithKline Plc
      • 12.3.7.1 Company Overview
      • 12.3.7.2 Product Portfolio
      • 12.3.7.3 Financials
      • 12.3.7.4 SWOT Analysis
    • 12.3.8 Pfizer Inc.
      • 12.3.8.1 Company Overview
      • 12.3.8.2 Product Portfolio
      • 12.3.8.3 Financials
      • 12.3.8.4 SWOT Analysis
    • 12.3.9 Sanofi S.A.
      • 12.3.9.1 Company Overview
      • 12.3.9.2 Product Portfolio
      • 12.3.9.3 Financials
      • 12.3.9.4 SWOT Analysis
    • 12.3.10 Teva Pharmaceutical Industries Ltd.
      • 12.3.10.1 Company Overview
      • 12.3.10.2 Product Portfolio
      • 12.3.10.3 Financials
      • 12.3.10.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Benign Prostatic Hyperplasia Treatment Market: Major Drivers and Challenges
  • Figure 2: Global: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Benign Prostatic Hyperplasia Treatment Market: Breakup by Treatment Type (in %), 2023
  • Figure 4: Global: Benign Prostatic Hyperplasia Treatment Market: Breakup by Region (in %), 2023
  • Figure 5: Global: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 6: Global: Benign Prostatic Hyperplasia Treatment (Drug Class) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 7: Global: Benign Prostatic Hyperplasia Treatment (Drug Class) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 8: Global: Benign Prostatic Hyperplasia Treatment (Minimally Invasive Surgeries) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Benign Prostatic Hyperplasia Treatment (Minimally Invasive Surgeries) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Benign Prostatic Hyperplasia Treatment (Laser Therapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Benign Prostatic Hyperplasia Treatment (Laser Therapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Benign Prostatic Hyperplasia Treatment (Other Treatment Types) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Benign Prostatic Hyperplasia Treatment (Other Treatment Types) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: North America: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: North America: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: United States: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: United States: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Canada: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Canada: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Asia Pacific: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Asia Pacific: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: China: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: China: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Japan: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Japan: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: India: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: India: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: South Korea: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: South Korea: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: Australia: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: Australia: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: Indonesia: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: Indonesia: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: Others: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: Others: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: Europe: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: Europe: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: Germany: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: Germany: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: France: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: France: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: United Kingdom: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: United Kingdom: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: Italy: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: Italy: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Spain: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Spain: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Russia: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Russia: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Others: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Others: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: Latin America: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: Latin America: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: Brazil: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: Brazil: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: Mexico: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: Mexico: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: Others: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: Others: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Middle East and Africa: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Middle East and Africa: Benign Prostatic Hyperplasia Treatment Market Forecast: Breakup by Country (in %), 2023
  • Figure 62: Middle East and Africa: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: Global: Benign Prostatic Hyperplasia Treatment Industry: SWOT Analysis
  • Figure 64: Global: Benign Prostatic Hyperplasia Treatment Industry: Value Chain Analysis
  • Figure 65: Global: Benign Prostatic Hyperplasia Treatment Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Benign Prostatic Hyperplasia Treatment Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Benign Prostatic Hyperplasia Treatment Market Forecast: Breakup by Treatment Type (in Million US$), 2024-2032
  • Table 3: Global: Benign Prostatic Hyperplasia Treatment Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 4: Global: Benign Prostatic Hyperplasia Treatment Market: Competitive Structure
  • Table 5: Global: Benign Prostatic Hyperplasia Treatment Market: Key Players